Cyclo(CRVIIF)

• UNSPSC Description:

  Cyclo CRVIIF is a dual inhibitor for hypoxia inducible factor (HIF) 1 and 2, which disrupts the interaction of both HIF1-α and HIF2-α with HIF1-β, with affinity for HIF1-α and HIF2-α PAS-B domains KD of 65 and 123 μM, respectively[1].

• Target Antigen:

  HIF/HIF Prolyl-Hydroxylase

• Type:

  Peptides

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cyclo-crviif.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@H]1CC2=CC=CC=C2)=O)=O)=O)=O)[C@H](CS)NC1=O

• Molecular Weight:

  731.95

• References & Citations:

  [1]Ball AT, et al., Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors 1 and 2 That Disrupt Hypoxia-Response Signaling in Cancer Cells. J Am Chem Soc. 2024 Mar 19.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported